MariaCPalanca-WesselsMDPhD

Oncology • Seattle, WA

Acting Assistant Professor, Medicine, University of Washington School of Medicine

Join to view full profile

Dr. Palanca-Wessels is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Palanca-Wessels' full profile

Already have an account?

Office
916 23rd Ave East
Seattle, WA 98112
Is this information wrong?

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 2003 - 2008
University of WashingtonFellowship, Hematology and Medical Oncology, 2003 - 2006
University of WashingtonResidency, Internal Medicine, 2001 - 2003
University of Washington School of MedicineClass of 2001

Certifications & Licensure

WA State Medical License 2003 - 2024
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Systematic literature review and meta-analysis of HER2 amplification, overexpression, and positivity in colorectal cancer.
Harshabad Singh, Ashley Kang, Lisa Bloudek, Ling-I Hsu, Maria Corinna Palanca-Wessels, Michael Stecher, Muriel Siadak, Kimmie Ng> ;JNCI Cancer Spectrum. 2024 Jan 4
1 citations
Real-World Treatment Patterns in Patients With HER2-Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database Study.
John H Strickler, Ling-I Hsu, Phoebe Wright, Michael Stecher, Muriel F Siadak, Maria Corinna Palanca-Wessels, Junhua Yu, Nicole Zhang, Carin R Espenschied, Kathryn Lan...> ;Journal of the National Comprehensive Cancer Network. 2023 Aug 1
19 citations
Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.
Maureen Ryan, Maria Corinna Palanca-Wessels, Brian Schimpf, Kristine A. Gordon, Heather Kostner, Brad Meyer, Changpu Yu, Heather A. Van Epps, Dennis Benjamin> ;Blood. 2017 Nov 2
355 citations
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
H. Miles Prince, Youn H. Kim, Steven M. Horwitz, Reinhard Dummer, Julia Scarisbrick, Pietro Quaglino, Pier Luigi Zinzani, Pascal Wolter, Jose A Sanches, Pablo L. Ortiz...> ;Lancet. 2017 Aug 5
43 citations
Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.
Nancy L. Bartlett, Mitchell R. Smith, Tanya Siddiqi, Ranjana H. Advani, Owen A. O'Connor, Jeff P. Sharman, Tatyana Feldman, Kerry J. Savage, Andrei R. Shustov, Catheri...> ;Leukemia & Lymphoma. 2017 Jul 3
33 citations
Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells
Maria Corinna Palanca-Wessels, Garrett C. Booth, Anthony J. Convertine, Brittany B. Lundy, Geoffrey Y. Berguig, Michael F. Press, Patrick S. Stayton, Oliver W. Press> ;Oncotarget. 2016 Jan 30
95 citations
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older
Andres Forero-Torres, Beata Holkova, Jerome H. Goldschmidt, Robert T. Chen, Gregg Olsen, Ralph V. Boccia, Rodolfo Bordoni, Jonathan W. Friedberg, Jeff P. Sharman, Mari...> ;Blood. 2015 Dec 24
5 citations
Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.
Andrew J. Cowan, Shani L. Frayo, Oliver W. Press, Maria Corinna Palanca-Wessels, John M. Pagel, Damian J. Green, Ajay K. Gopal> ;Anti-Cancer Drugs. 2015 Oct 1
98 citations
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
Matthias Pfeifer, Bing Zheng, Tabea Erdmann, Hartmut Koeppen, Ronald McCord, Michael Grau, Annette M. Staiger, Akiko Chai, Thomas Sandmann, Hannelore Madle, Bernd Dörk...> ;Leukemia. 2015 Jul 1
206 citations
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaem...
Maria Corinna Palanca-Wessels, Myron S. Czuczman, Gilles Salles, Sarit Assouline, Laurie H. Sehn, Ian W. Flinn, Manish R. Patel, Randeep Sangha, Anton Hagenbeek, Ranja...> ;The Lancet. Oncology. 2015 Jun 1
24 citations
Intracellular Delivery System for Antibody–Peptide Drug Conjugates
Geoffrey Y. Berguig, Anthony J. Convertine, Shani L. Frayo, Hanna B. Kern, Erik Procko, Debashish Roy, Selvi Srinivasan, Daciana Margineantu, Garrett C. Booth, Maria C...> ;Molecular Therapy. 2015 May 1
211 citations
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
Eric D. Jacobsen, Jeff P. Sharman, Yasuhiro Oki, Ranjana H. Advani, Jane N. Winter, Celeste M. Bello, Gary Spitzer, Maria Corinna Palanca-Wessels, Dana A. Kennedy, Pam...> ;Blood. 2015 Feb 26
5 citations
Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity.
Colin Phipps, Ajay K. Gopal, Barry E. Storer, Ryan D. Cassaday, Oliver W. Press, Brian G. Till, John M. Pagel, Maria Corinna Palanca-Wessels, Mary Philip, William I. B...> ;Leukemia & Lymphoma. 2015 Jan 1
38 citations
Advances in the treatment of hematologic malignancies using immunoconjugates.
Maria Corinna Palanca-Wessels, Oliver W. Press> ;Blood. 2014 Apr 10
26 citations
Specific Features Identify Patients with Relapsed or Refractory Mantle Cell Lymphoma Benefitting from Autologous Hematopoietic Cell Transplantation
Ryan D. Cassaday, Katherine A. Guthrie, Elizabeth L. Budde, Leslie Thompson, Brian G. Till, Oliver W. Press, Thomas R. Chauncey, John M. Pagel, Stephen H. Petersdorf, ...> ;Biology of Blood and Marrow Transplantation. 2013 Sep 1
7 citations
Selection of First-Line Therapy for Advanced Follicular Lymphoma
Oliver W. Press, Maria Corinna Palanca-Wessels> ;Journal of Clinical Oncology. 2013 Apr 20
30 citations
Intracellular delivery and trafficking dynamics of a lymphoma-targeting antibody-polymer conjugate.
Geoffrey Y. Berguig, Anthony J. Convertine, Julie Shi, Maria Corinna Palanca-Wessels, Craig L. Duvall, Suzie H. Pun, Oliver W. Press, Patrick S. Stayton> ;Molecular Pharmaceutics. 2012 Dec 3
37 citations
Anti-CD22 Antibody Targeting of pH-responsive Micelles Enhances Small Interfering RNA Delivery and Gene Silencing in Lymphoma Cells
Maria Corinna Palanca-Wessels, Anthony J. Convertine, Richelle Cutler-Strom, Garrett C. Booth, Fan Lee, Geoffrey Y. Berguig, Patrick S. Stayton, Oliver W. Press> ;Molecular Therapy. 2011 Aug 1
65 citations
Genetic analysis of long-term Barrett's esophagus epithelial cultures exhibiting cytogenetic and ploidy abnormalities.
Maria Corinna Palanca-Wessels, Michael T. Barrett, Patricia C. Galipeau, K. L. Rohrer, Brian J. Reid, Peter S. Rabinovitch> ;Gastroenterology. 1998 Feb 1
Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas.
Palanca-Wessels, M. C., Press, O. W.> ;Cancer. 2010 Feb 15
58 citations
Extended lifespan of Barrett's esophagus epithelium transduced with the human telomerase catalytic subunit: A useful in vitro model
M. Corinna A. Palanca-Wessels, Aloysius J. Klingelhutz, Brian J. Reid, Thomas H. Norwood, Kent E. Opheim, Thomas G. Paulson, Ziding Feng, Peter S. Rabinovitch> ;Carcinogenesis. 2003 Jul 1
Join now to see all

Press Mentions

ALCANZA Study: Brentuximab Vedotin Superior in CD30-Expressing Cutaneous T Cell LymphomaDecember 3rd, 2016

Hospital Affiliations

UW Medicine/Harborview Medical CenterSeattle, Washington